Bivalirudin
Links shared publicly online about this topic
Symposier - Dr. Nilesh Goswami on Bivalirudin use in ST elevation MI
symposier.com — “Uploaded and Shared in Youtube by: cathu2 Nilesh J. Goswami, MD [of the Prairie Heart Institute at St. John's Hospital (in Springfield, Illinois)]discusses the use of IV Bivalirudin during percutaneous coronary interventions for acute ST elevation myocardial infarction. The HORIZONS study is highlighted and data from real world experience is presented.” View full resource at symposier.com
Most Recently Shared on January 19, 2010 at 5:59 pm By:
Symposier Cardiology Cardiology and Health Business
Bivalirudin use in ST Elevation MI --> http://bit.ly/7CMgpZ
BIVALIRUDIN Ppt Powerpoint Presentation slides sameer Medical Slideshow Safety and Efficacy of Crossover Switch from UFH/Enox to Bivalirudin: Results from ACUITY
slideworld.org — “Powerpoint BIVALIRUDIN Slides by sameer JNMC & KLE hospital,Belgaum ,India Safety and Efficacy of Crossover Switch from UFH/Enox to Bivalirudin: Results from ACUITY Download Free Medical Powerpoint Presentations” View full resource at slideworld.org
Most Recently Shared on June 29, 2009 at 2:41 pm By:
Medical Templates Health Organization
BIVALIRUDIN: cardiac drugs,direct thrombin inhibitor- Slides http://tinyurl.com/m43ly3
Bivalirudin Dosing Adjustments for Reduced Renal Function With or Without Hemodialysis in the Management of Heparin-Induced Thrombocytopenia (October)
theannals.com — “Bivalirudin Dosing Adjustments for Reduced Renal Function With or Without Hemodialysis in the Management of Heparin-Induced Thrombocytopenia (October)” View full resource at theannals.com
Most Recently Shared on September 2, 2011 at 3:23 am By:
Bivalirudin Dosing Adjustments for Reduced Renal Function With or Without Hemodialysis in the Management of He... http://t.co/TywBauy
After Thrombolytic Therapy for Primary PCI, Bivalirudin Has Similar Results to Unfractionated Heparin - ONA
oncologynurseadvisor.com — “Use of bivalirudin after initial management with thrombolytics appears to be as safe as unfractionated heparin for primary percutaneous coronary intervention, according to the results of a retrospective study presented at ACC.11, the American College of Cardiology--™s 60th Annual Scientific Session.” View full resource at oncologynurseadvisor.com
Most Recently Shared on April 4, 2011 at 10:18 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
After Thrombolytic Therapy for Primary PCI, Bivalirudin Has Similar Results to Unfractionated… http://goo.gl/fb/kNtrf
TCT: Last Word Positive on Trial of Bivalirudin (CME/CE) - QualityPoint Technologies
qualitypointtech.net — “WASHINGTON (MedPage Today) -- The final report from the HORIZONS-AMI trial revealed an increasing mortality benefit for ST-elevation MI patients treated with bivalirudin (Angiomax) -- compared with those who received unfractioned heparin plus abciximab (ReoPro) or eptifibatide (Integrelin), according to the trial's lead investigator.” View full resource at qualitypointtech.net
Most Recently Shared on September 27, 2010 at 3:48 pm By:
TCT: Last Word Positive on Trial of Bivalirudin (CME/CE): WASHINGTON (MedPage Today) -- The final report from the ... http://bit.ly/aEZCGI
Bivalirudin Reduces Mortality After PCI for High-Risk STEMI: Post Hoc Analysis - QualityPoint Technologies
qualitypointtech.net — “In high-risk patients having percutaneous coronary intervention for ST-segment elevation acute myocardial infarction (STEMI), bivalirudin was more effective than unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor (UFH/GPI) in reducing mortality and repeat myocardial infarction. Reuters Health Information” View full resource at qualitypointtech.net
Most Recently Shared on August 17, 2010 at 9:18 pm By:
Bivalirudin Reduces Mortality After PCI for High-Risk STEMI: Post Hoc Analysis: In high-risk patients having percu... http://bit.ly/df2fyx
Use of Low-Dose Heparin With Bivalirudin for Ad-hoc Transradial Coronary Interventions - QualityPoint Technologies
qualitypointtech.net — “How do the safety and efficacy profiles compare with combined low-dose Heparin and Bivalrudin in femoral vs. transradial PCI? The Journal of Invasive Cardiology” View full resource at qualitypointtech.net
Most Recently Shared on July 19, 2011 at 2:00 pm By:
Use of Low-Dose Heparin With Bivalirudin for Ad-hoc Transradial Coronary Interventions: How do the safety and effi... http://bit.ly/p57NZ1
Efficacy and Safety of Bivalirudin in Patients with Diabetes Mellitus (Full title below) | Journal of Invasive Cardiology
invasivecardiology.com — “Efficacy and Safety of Bivalirudin in Patients with Diabetes Mellitus (Full title below) | Journal of Invasive Cardiology” View full resource at invasivecardiology.com
Most Recently Shared on March 5, 2010 at 4:33 pm By:
Invasive Cardiology Medical Journal and Cardiology
In diabetes patients, bivalirudin monotherapy offers similar protection during PCI compared to UFH + GP IIb/IIIa. http://tinyurl.com/yc5rrky
ISAR-REACT 4 on bivalirudin; IC vs IV abciximab in AIDA STEMI; vorapaxar in TRACER; ADOPT: apixaban vs enoxaparin; rivaroxaban in ATLAS ACS 2
blogs.theheart.org — “ISAR-REACT 4 on bivalirudin; IC vs IV abciximab in AIDA STEMI; vorapaxar in TRACER; ADOPT: apixaban vs enoxaparin; rivaroxaban in ATLAS ACS 2” View full resource at blogs.theheart.org
Most Recently Shared on November 14, 2011 at 4:33 am By:
Dr Walton-Shirley Physician, Doctor, Internist, and Cardiologist
ISAR-REACT 4 on bivalirudin; IC vs IV abciximab in AIDA STEMI; vorapaxar in TRACER; ADOPT:...: ISAR-REACT 4 on b... http://t.co/NFgpkRaX
Two-year HORIZONS-AMI data
theheart.org — “Two-year data showed significant reductions in bleeding and cardiac mortality in patients treated with bivalirudin when compared with those treated with heparin plus a GP IIb/IIIa inhibitor. In the stent arm of the trial, researchers showed that stent thrombosis rates were equivalent between DES and bare-metal stents, although both rates were high, at 4.1%.” View full resource at theheart.org
Most Recently Shared on September 25, 2009 at 10:43 pm By:
heartwire: Reduced bleeding and comparable stent thrombosis with DES and bare-metal stents: HORIZONS-.. http://bit.ly/3A6wbs
At TCT 2009: One-Year Results From Horizons-AMI Trial
medicalnewstoday.com — “Two subset analyses from the landmark horizons-ami trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a gp iib/iiia inhibit” View full resource at medicalnewstoday.com
Most Recently Shared on September 23, 2009 at 10:18 am By:
MedicalNewsToday: At TCT 2009: One-Year Results From Horizons-AMI Trial http://bit.ly/Yb7wc Full http://bit.ly/SUzv4
Study Identifies Treatments Associated With Lower Bleeding Rates Following Cardiac Procedures Such As Angioplasty
medicalnewstoday.com — “In a study that included data from more than 1.5 million patients, use of vascular closure devices and the anticoagulant bivalirudin were associated with significantly lower bleeding rates for pat” View full resource at medicalnewstoday.com
Most Recently Shared on June 2, 2010 at 12:17 pm By:
Study Identifies Treatments Associated With Lower Bleeding Rates Following Cardiac Procedures Such As Angioplasty http://mnt.to/3Dnn
Meta-analysis: bleeding and mortality
theheart.org — “A new pooled analysis of REPLACE-2, ACUITY, and HORIZONS-AMI drums home the need for one universal definition of bleeding to be used in all trials, and efforts to make this happen are under way.” View full resource at theheart.org
Most Recently Shared on September 2, 2009 at 7:53 pm By:
heartwire: Non-TIMI major bleeding just as important as TIMI major bleeding in predicting morta.. http://bit.ly/AHPdO #ESC09
Clopidogrel 600 mg in primary PCI
theheart.org — “The higher dose was associated with a reduced rate of ischemic events without an increase in bleeding in patients with STEMI undergoing primary PCI.” View full resource at theheart.org
Most Recently Shared on October 1, 2009 at 8:45 pm By:
heartwire: HORIZONS analysis: 600-mg clopidogrel load preferable in primary PCI http://bit.ly/492i7E
Angiomax Reduced Cardiac Mortality by 41%; Reduced Overall Mortality by 25% in Severe Heart Attack Patients Following Angioplasty - Drugs.com MedNews
drugs.com — “HORIZONS-AMI Trial Two-Year Results Presented at TCT PARSIPPANY, NJ, Sep 25, 2009 (MARKETWIRE The Medicines Company (NASDAQ MDCO) today announced the presentati” View full resource at drugs.com
Most Recently Shared on September 26, 2009 at 6:22 am By:
Tammi Jacobs Health Professional
Angiomax Reduced Cardiac Mortality by 41%; Reduced Overall ... http://bit.ly/1FOMh2
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Featuring the top 3 experts for this topic
-
Symposier Cardiology
Symposier.com, the technological platform that will allow you (and your colleagues) to share medical information, and much more with medicine professionals.
-
Medical Templates
Download medical powerpoint templates on all medical related topics for making fabulous medical powerpoint presentations.
-
The Annals
The Annals of Pharmacotherapy is a peer-reviewed medical journal advancing drug therapy by publishing evidence-based pharmacy research and clinical reviews.
Advertisement
